Loading...

DARE DARE BIOSCIENCE INC Capital Structure Changes 8-K Filing

DR B

DR

DARE BIOSCIENCE INC

(DARE)

2025 8-K

Show Summary

Summary

Clinical Trials

Rights Offerings

Investor Meetings

Earnings Releases

Nasdaq Compliance Extension

Financial Results

Nasdaq Delisting Notice

Investor Presentation

Corporate Presentation

Clinical Study Plans

Financial Results

Investor Presentation

Funding Agreement

Stock Purchase Agreement

Financial Results

Compliance regained with Na...

Reverse Stock Split

Annual Meeting of Stockholders

Earnings Report

Agreements with XOMA

Financial Results Announcement

Management Changes

Corporate Presentation

Royalty Interest Financing ...

Phase 1 Clinical Study Results

Changes in Registrant's Cer...

Financial Results Announcement

Phase 2b RESPOND study resu...

Commercial Milestone Achiev...

Financial Results and Audit...

Forced Delisting

Contract Renewal

Annual Meeting of Stockholders

Clinical Trial Results

Earnings Reports

Sales Agreement

Earnings Reports

Presentation Release

Presentation Release

By-laws Amendment

Compliance with Nasdaq Mini...

Clinical Study Results

External Links:

On April 9, 2025, DARE Bioscience, Inc. received an extension until August 12, 2025, from Nasdaq to demonstrate compliance with listing rules regarding stockholders' equity of at least $2.5 million or a market value of $35 million, after being non-compliant since August 2024.

AI Assistant

DARE BIOSCIENCE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.